Day One Biopharmaceuticals Inc (NASDAQ: DAWN) is -14.66% lower on its value in year-to-date trading and has touched a low of $11.94 and a high of $18.07 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DAWN stock was last observed hovering at around $12.53 in the last trading session, with the day’s loss setting it -0.07%.
Currently trading at $12.46, the stock is -6.23% and -11.57% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing -0.56% at the moment leaves the stock -13.37% off its SMA200. DAWN registered -13.89% loss for a year compared to 6-month loss of -8.92%. The firm has a 50-day simple moving average (SMA 50) of $14.1224 and a 200-day simple moving average (SMA200) of $14.3993.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.84% gain in the last 1 month and extending the period to 3 months gives it a -15.70%, and is -2.73% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.29% over the week and 3.76% over the month.
Day One Biopharmaceuticals Inc (DAWN) has around 155 employees, a market worth around $1.26B and $101.95M in sales. Profit margin for the company is -82.68%. Distance from 52-week low is 4.36% and -31.05% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.11%).
with sales reaching $26.6M over the same period.The EPS is expected to grow by 67.85% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
253.0 institutions hold shares in Day One Biopharmaceuticals Inc (DAWN), with institutional investors hold 112.29% of the company’s shares. The shares outstanding are 100.81M, and float is at 72.64M with Short Float at 26.83%. Institutions hold 93.22% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.87 million shares valued at $108.47 million. The investor’s holdings represent 9.0814 of the DAWN Shares outstanding. As of 2024-06-30, the second largest holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 6.43 million shares valued at $88.61 million to account for 7.4184 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 4.62 million shares representing 5.3338 and valued at over $63.71 million, while BLACKROCK INC. holds 5.2301 of the shares totaling 4.53 million with a market value of $62.47 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
The most recent transaction is an insider sale by Blackman Samuel C., the company’s HEAD OF R&D. SEC filings show that Blackman Samuel C. sold 30,000 shares of the company’s common stock on Dec 10 ’24 at a price of $13.31 per share for a total of $0.4 million. Following the sale, the insider now owns 1.03 million shares.
Day One Biopharmaceuticals Inc disclosed in a document filed with the SEC on Nov 18 ’24 that Bender Jeremy (CHIEF EXECUTIVE OFFICER) sold a total of 10,554 shares of the company’s common stock. The trade occurred on Nov 18 ’24 and was made at $13.21 per share for $0.14 million. Following the transaction, the insider now directly holds 0.11 million shares of the DAWN stock.
Still, SEC filings show that on Nov 18 ’24, Blackman Samuel C. (HEAD OF R&D) disposed off 2,206 shares at an average price of $13.21 for $29142.0. The insider now directly holds 1,064,015 shares of Day One Biopharmaceuticals Inc (DAWN).
